The use of colony-stimulating factors in primary hematologic disorders

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background. The cloning of the human colony-stimulating factors (CSF), granulocyte CSF, granulocyte-macrophage CSF, and interleukin-3 has led to their use in a variety of clinical settings. Results. These CSF have been used successfully to raise neutrophil counts and prevent or control infection in patients with neutropenia due to primary hematologic disorders. Their effects on platelet and erythrocyte counts have been modest; occasional patients have multi-lineage improvement in hematopoiesis. Conclusions. The CSF can be given for several months at effective and tolerable doses. Their long-term efficacies and toxicities remain to be elucidated, and the optimal dose and dosing schedule to be used for each indication are not defined currently. Although the CSF can improve hematopoiesis in patients with primary hematologic disorders, they are not curative.

Original languageEnglish
Pages (from-to)921-927
Number of pages7
JournalCancer
Volume70
Issue number4 SUPPL.
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Colony-Stimulating Factors
Hematopoiesis
Erythrocyte Count
Interleukin-3
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Infection Control
Neutropenia
Platelet Count
Organism Cloning
Appointments and Schedules
Neutrophils

Keywords

  • AIDS (acquired immune deficiency syndrome)
  • aplastic anemia
  • colony-stimulating factor (CSF)
  • hematopoiesis
  • myelodysplastic syndrome
  • neutropenia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The use of colony-stimulating factors in primary hematologic disorders. / Nimer, Stephen D.

In: Cancer, Vol. 70, No. 4 SUPPL., 01.01.1992, p. 921-927.

Research output: Contribution to journalArticle

@article{530515c4294a4bea8b3a6fd9b8c5de0a,
title = "The use of colony-stimulating factors in primary hematologic disorders",
abstract = "Background. The cloning of the human colony-stimulating factors (CSF), granulocyte CSF, granulocyte-macrophage CSF, and interleukin-3 has led to their use in a variety of clinical settings. Results. These CSF have been used successfully to raise neutrophil counts and prevent or control infection in patients with neutropenia due to primary hematologic disorders. Their effects on platelet and erythrocyte counts have been modest; occasional patients have multi-lineage improvement in hematopoiesis. Conclusions. The CSF can be given for several months at effective and tolerable doses. Their long-term efficacies and toxicities remain to be elucidated, and the optimal dose and dosing schedule to be used for each indication are not defined currently. Although the CSF can improve hematopoiesis in patients with primary hematologic disorders, they are not curative.",
keywords = "AIDS (acquired immune deficiency syndrome), aplastic anemia, colony-stimulating factor (CSF), hematopoiesis, myelodysplastic syndrome, neutropenia",
author = "Nimer, {Stephen D}",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "70",
pages = "921--927",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - The use of colony-stimulating factors in primary hematologic disorders

AU - Nimer, Stephen D

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Background. The cloning of the human colony-stimulating factors (CSF), granulocyte CSF, granulocyte-macrophage CSF, and interleukin-3 has led to their use in a variety of clinical settings. Results. These CSF have been used successfully to raise neutrophil counts and prevent or control infection in patients with neutropenia due to primary hematologic disorders. Their effects on platelet and erythrocyte counts have been modest; occasional patients have multi-lineage improvement in hematopoiesis. Conclusions. The CSF can be given for several months at effective and tolerable doses. Their long-term efficacies and toxicities remain to be elucidated, and the optimal dose and dosing schedule to be used for each indication are not defined currently. Although the CSF can improve hematopoiesis in patients with primary hematologic disorders, they are not curative.

AB - Background. The cloning of the human colony-stimulating factors (CSF), granulocyte CSF, granulocyte-macrophage CSF, and interleukin-3 has led to their use in a variety of clinical settings. Results. These CSF have been used successfully to raise neutrophil counts and prevent or control infection in patients with neutropenia due to primary hematologic disorders. Their effects on platelet and erythrocyte counts have been modest; occasional patients have multi-lineage improvement in hematopoiesis. Conclusions. The CSF can be given for several months at effective and tolerable doses. Their long-term efficacies and toxicities remain to be elucidated, and the optimal dose and dosing schedule to be used for each indication are not defined currently. Although the CSF can improve hematopoiesis in patients with primary hematologic disorders, they are not curative.

KW - AIDS (acquired immune deficiency syndrome)

KW - aplastic anemia

KW - colony-stimulating factor (CSF)

KW - hematopoiesis

KW - myelodysplastic syndrome

KW - neutropenia

UR - http://www.scopus.com/inward/record.url?scp=0026762292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026762292&partnerID=8YFLogxK

M3 - Article

C2 - 1638464

AN - SCOPUS:0026762292

VL - 70

SP - 921

EP - 927

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4 SUPPL.

ER -